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Abstract
The medical research community is experiencing a marked increase in the amount of
information available on genomic sequences and genes expressed by humans and other
organisms. This information offers great opportunities for improving our understanding of
complex diseases such as lung cancer. In particular, we should expect to witness a rapid
increase in the rate of discovery of genes involved in lung cancer pathogenesis and we
should be able to develop reliable molecular criteria for classifying lung cancers and
predicting biological properties of individual tumors. Achieving these goals will require
collaboration by scientists with specialized expertise in medicine, molecular biology, and
decision-based statistical analysis.
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Introduction
Genomics – the discipline that characterizes the struc-
tural and functional anatomy of the genome – has
attracted continuously increased interest and invest-
ment over the past decade. The complete sequencing
of the human genome is expected within a few years;
together with the identification of expressed sequences
and polymorphic sequences, a vast information infra-
structure will be available to medical researchers
throughout the world.
The rationale for this ambitious project is now well known
to the medical community. The discovery of genes
involved in the pathogenesis of human diseases will, it is
hoped, lead to new targets for diagnosis and treatment of
those diseases. Knowing the polymorphisms that make
each of us unique individuals could be the key in the future
to predicting individual risks for developing disease and
individual responses to pharmacological agents. However,
the full impact of genomics on medical research is still
unknown. Acknowledging the limitations of predicting the
role of genomics far in the future, this paper limits its dis-
cussion to current applications of genomics to research
on lung cancer.
Genomics and gene discovery
A new era of gene discovery began in 1991, when Craig
Venter and colleagues reported the sequencing of ran-
domly selected human brain cDNA clones [1]. In this pilot
project, 337 of the sequences, termed expressedhttp://respiratory-research.com/content/1/1/036
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sequence tags (ESTs), were found to represent new
human genes. Over the following years, this strategy has
been used by many laboratories to sequence several
hundred thousand ESTs, representing most of the genes
discovered so far.
However, the era for the actual discovery of new genes
has a finite life. Programs such as the Cancer Genome
Anatomy Project [2], sponsored by the biotechnology
industry and by government, have probably sequenced
ESTs for nearly all of the estimated 100000–120000
total human genes, and much of this information is cur-
rently in public-domain databases. The sequencing of the
whole genome and the prediction of coding regions from
genomic sequences will probably complete the ‘discovery’
of gene sequences within a few years.
However, only approximately 5000 genes have known
functions or even names, so there will remain much to be
learned about how the genes function in health and
disease. Thus, cancer researchers will have great opportu-
nities in the next few years to mine genomics databases
and identify candidates for genes important in cancer
pathogenesis. A good example of such mining of genome
databases is the discovery of a new tumor suppressor
gene for lung and colon cancers on human chromosome
11 [3]. After localizing a region of frequent chromosomal
deletions in lung cancer to a locus at 11q22–24, Wang
and colleagues searched genome databases for genes
previously mapped to that locus. One gene, PPP2R1B,
was found to have somatic mutations in lung cancers and
the altered gene products were then found to have func-
tional consequences that would be expected to contribute
to the malignant phenotype.
The discovery of PPP2R1B as a gene for a lung cancer
tumor suppressor serves as an example of how genomics
databases will probably make traditional positional cloning
unnecessary. Numerous other chromosomal aberrations
and loci of chromosomal deletions have already been
defined for lung cancer and, with the increasing availability
of gene maps, the next few years are likely to see an
acceleration in our recognition of new genes involved in
lung cancer pathogenesis.
Functional genomics and lung cancer
Some of the most exciting applications of genomics to
cancer research come from measurements of the gene
expression of cancer cells with the use of high-throughput
technologies. SAGE (serial analysis of gene expression),
oligonucleotide arrays, and cDNA arrays are new tools
that allow investigators to measure the expression of thou-
sands of genes in a single experiment. Experiments using
such approaches are leading to additional discoveries of
genes involved in cancer pathogenesis and providing new
strategies for classifying cancers.
With SAGE, short tags of mRNA (eg nine bases) are cut
from defined positions, serially linked together, and
sequenced to provide a quantitative measurement of
genes expressed in a sample [4]. For lung cancer, Jen and
colleagues at Johns Hopkins sequenced and analyzed
over 226000 tags from two primary lung cancers and two
bronchial epithelial cell cultures, finding 175 transcripts to
be significantly underexpressed and 142 transcripts to be
significantly overexpressed in the cancers in comparison
with normal cells [5]. A few of the genes are being studied
further for their role in lung cancer pathogenesis, but
clearly this single experiment has opened the door to a
large number of future studies.
Wang and colleagues at Corixa recently reported an alter-
native approach to the discovery of lung cancer genes [6].
This group first used subtractive hybridization to isolate
cDNA clones highly expressed in squamous cell lung
cancers. Analyzing the expression of a larger number of
specimens by using cDNA arrays representing the
selected clones, genes overexpressed in squamous cell
cancers – and potential therapeutic targets – were found.
Both of these projects used ‘open’ gene discovery strate-
gies, in which all genes present could potentially be
detected. Most gene arrays, in contrast, are ‘closed’
systems for measuring gene expression because the mea-
surements are limited to the genes represented on the
arrays. However, arrays are being constructed that repre-
sent increasingly large numbers of genes, and the effi-
ciency and relatively low cost of arrays, particularly cDNA
arrays [7], will probably lead to the increasing use of this
technology for gene discovery.
Genomics and classification of lung cancer
Developing a well-defined taxonomy for cancer is impor-
tant, both for clinical management of the disease and for
cancer research. Because of implications for treatment
and prognosis, few would question the significance of dif-
ferentiating lymphoma from carcinoma, or small cell carci-
noma from non-small cell carcinoma in the evaluation of a
lung tumor. However, our inability to subclassify lung
cancer further is not frequently recognized as a critical
deficiency. Most clinical lung cancer research recognizes
the standard morphological classification of lung cancers,
which is unable to provide critical information on the
aggressiveness of a particular cancer or how the cancer
will respond to radiation therapy or chemotherapy.
There has been a long-standing hope that molecular
markers will help to predict important clinical features of
cancers. In most molecular studies, candidate markers
were tested individually for their association with outcome.
More recently, genomics and technologies such as gene
arrays have offered the opportunity to test large numbers
of genes as potential predictive markers. Because theRespiratory Research    Vol 1 No 1 Gabrielson
number of variables measured invariably exceeds the
number of samples in such studies, some skeptics have
argued that any association between a single marker and
an outcome would be meaningless by traditional statistical
criteria. To address this problem, statisticians have quickly
begun to apply decision-based analysis strategies to sort
through gene expression data. For example, self-organiz-
ing maps, originally designed for functions such as voice
recognition, and hierarchical clustering methods, long
used in biological classifications, have been designed to
focus on overall patterns of gene expression rather than
on individual genes.
The most significant advances in the use of genomics to
classify cancers so far have been made with leukemia and
lymphoma. A study of myelogenous and lymphocytic
leukemias at Harvard with gene arrays demonstrated the
ability to find distinguishing gene expression profiles of
previously defined classes (class distinction) as well as to
rediscover the two classes by gene expression profiles
alone (class discovery) [8]. In another study, a collabora-
tive group from Stanford and the NCI found two molecu-
larly distinct forms of diffuse large B-cell lymphoma
(DLBCL) on the basis of gene expression profiles, and
showed the two categories to have significantly different
prognoses [9]. Interestingly, differentiation genes were
major distinguishing features between the two subclasses
of DLBCL, suggesting that the two types of DLBCL arise
from different progenitor cells. These different patterns of
differentiation can be distinguished by gene expression
profiles but not by morphology.
Will gene expression profiles also help to distinguish
between different phenotypes of lung cancer? The
problem of classifying lung cancer might be more difficult
than that for subclassifying hematopoietic neoplasms,
because leukemia and lymphoma already have strong
pre-existing classification frameworks, permitting the study
of focused problems in taxonomy. In addition, tissue
samples of leukemia and lymphoma typically have a great
predominance of neoplastic cells, whereas tissue samples
of lung cancer often have more lymphocytes and stromal
cells than cancer cells. Thus, the analysis of lung cancer
specimens for gene expression will not be straightforward.
To address this problem of impure lung cancer tissue
samples, it will most probably be necessary first to purify
the cancer cells from the heterogeneous mix. Laser
capture microdissection is one technique that can be
applied to the purification of the neoplastic cells [10], and
recently a simple technique for scraping nearly pure clus-
ters of neoplastic cells from tumor tissues was developed
by the Gazdar laboratory at the University of Texas [11].
The development and utilization of such tissue-processing
methods will be essential for the successful execution of
molecular phenotyping projects.
Another key element for lung cancer classification projects
will be the development of reliable and reproducible tech-
nologies for measuring the genes that are most important
to lung cancer. One approach is to develop custom ‘pneu-
mochip’ arrays that represent the genes expressed in res-
piratory epithelium and lung cancer. Already, collaborative
efforts to develop such arrays are under way in major lung
cancer research programs.
High-throughput analysis of genomic
alterations in cancer
Although gene expression patterns are closely linked to
a cell’s function, it is ultimately genetic alterations that
are responsible for the cancer phenotype. Although
high-throughput technology for the analysis of mutations
in genomic DNA is not as developed as the technology
for the analysis of gene expression, some advances have
been made in this area. In particular, oligonucleotide
arrays can represent a series of different sequences for
each gene, including wild-type and single-base mis-
match sequences. This technology was found to be rea-
sonably effective for detecting p53 mutations in lung
cancers [12], but these arrays can only detect mutations
in the specific genes and of the specific mutated
sequences represented.
cDNA arrays have also been used as a substrate for com-
parative genomic hybridization (CGH) in pilot experiments
[13], and this could obviously be applied to the study of
lung cancer. With conventional CGH, differentially labeled
test and reference genomic DNAs are co-hybridized to
normal metaphase chromosomes, and fluorescence ratios
along the lengths of these chromosomes are used to esti-
mate variations in DNA copy number. Notably, CGH with
arrays will probably have significantly higher resolution
than CGH on metaphase chromosomes, and could detect
changes in chromosomal copy numbers occurring at the
single-gene level. Obviously, CGH by arrays could be
combined with gene expression levels by arrays to find
genes that have both an amplified gene copy number and
overexpression.
The future of genomics in lung cancer research
In the next few years, a considerable effort will be made
to classify lung cancers, to discover genes involved in
lung cancer pathogenesis, and to study the biochemistry
and function of those genes in lung cancers. The major
tools for tissue processing, array production, and deci-
sion-based statistical analysis strategies all seem to be in
place for these efforts. But clinical scientists, patholo-
gists, molecular biologists, statisticians, and informatics
specialists will all need to pull together to make lung
cancer genomics programs successful. Collaborative
efforts will probably be increasingly important in cancer
research because sophisticated tools require specialized
expertise.Predictions beyond these obvious research targets are not
so easy. Promising new high-throughput proteomics tech-
nologies might not only measure protein levels but might
also recognize post-translational modifications of proteins.
Integrating these measurements with those of gene
expression could add a whole new dimension to our
understanding of cancer. Furthermore, we must remember
that our current focus of genomics on gene expression vir-
tually ignores the 95% of the genome that does not
encode proteins or regulatory information. Although the
function of this vast amount of our genome is unknown, it
is often thought to be involved in stabilizing chomosomes
and thus should be considered a likely target for
cancer-related aberrations.
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